 | |
| Clinical data | |
|---|---|
| Other names | {2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl} propanoate |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a604021 |
| Routes of administration | Topical |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.070.516 |
| Chemical and physical data | |
| Formula | C27H36O8 |
| Molar mass | 488.577 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Prednicarbate is a relatively newtopicalcorticosteroid drug. It is similar in potency tohydrocortisone. Corticosteroids have always been an important part of the pharmacological arsenal ofdermatology; however, their tendency to produce side-effects has caused the need to search for new preparations.[1]
It is nonhalogenated.[2]
 | Thisdermatologicdrug article is astub. You can help Wikipedia byexpanding it. |